Search filters

List of works by Erasmia Psimenou

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

scientific article published on 4 April 2016

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

scientific article published on 27 February 2017

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

scientific article published on 03 November 2020

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

scientific article published on 03 October 2020

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

scientific article

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

scientific article published on 23 August 2020

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

scientific article published on 01 December 2018

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

scientific article published on 31 January 2018

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

scientific article

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

scientific article published on 20 February 2010

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

scientific article published on 9 March 2015

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

scientific article published on 01 October 2019

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

scientific article

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

scientific article published on 28 March 2017

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

scientific article published on 27 July 2020

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

scientific article published on 01 April 2007

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

scientific article published on 26 May 2010

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

scientific article published on 27 July 2020

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

scientific article

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

scientific article published on May 2008

Paulina is supported by:

About Paulina

Help